A low dose of RBD and TLR7/8 agonist displayed on influenza virosome particles protects rhesus macaque against SARS-CoV-2 challenge.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 03 2023
28 03 2023
Historique:
received:
13
01
2023
accepted:
17
03
2023
medline:
30
3
2023
entrez:
28
3
2023
pubmed:
29
3
2023
Statut:
epublish
Résumé
Influenza virosomes serve as antigen delivery vehicles and pre-existing immunity toward influenza improves the immune responses toward antigens. Here, vaccine efficacy was evaluated in non-human primates with a COVID-19 virosome-based vaccine containing a low dose of RBD protein (15 µg) and the adjuvant 3M-052 (1 µg), displayed together on virosomes. Vaccinated animals (n = 6) received two intramuscular administrations at week 0 and 4 and challenged with SARS-CoV-2 at week 8, together with unvaccinated control animals (n = 4). The vaccine was safe and well tolerated and serum RBD IgG antibodies were induced in all animals and in the nasal washes and bronchoalveolar lavages in the three youngest animals. All control animals became strongly sgRNA positive in BAL, while all vaccinated animals were protected, although the oldest vaccinated animal (V1) was transiently weakly positive. The three youngest animals had also no detectable sgRNA in nasal wash and throat. Cross-strain serum neutralizing antibodies toward Wuhan-like, Alpha, Beta, and Delta viruses were observed in animals with the highest serum titers. Pro-inflammatory cytokines IL-8, CXCL-10 and IL-6 were increased in BALs of infected control animals but not in vaccinated animals. Virosomes-RBD/3M-052 prevented severe SARS-CoV-2, as shown by a lower total lung inflammatory pathology score than control animals.
Identifiants
pubmed: 36977691
doi: 10.1038/s41598-023-31818-y
pii: 10.1038/s41598-023-31818-y
pmc: PMC10044094
doi:
Substances chimiques
Virosomes
0
Toll-Like Receptor 7
0
Influenza Vaccines
0
Adjuvants, Immunologic
0
Broadly Neutralizing Antibodies
0
COVID-19 Vaccines
0
Antibodies, Viral
0
Antibodies, Neutralizing
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5074Informations de copyright
© 2023. The Author(s).
Références
Expert Rev Vaccines. 2007 Oct;6(5):711-21
pubmed: 17931152
Environ Int. 2020 Jun;139:105730
pubmed: 32294574
PLoS One. 2007 Oct 10;2(10):e1018
pubmed: 17925866
J Exp Med. 2002 Aug 5;196(3):303-10
pubmed: 12163559
Front Immunol. 2021 Jul 12;12:701501
pubmed: 34322129
Signal Transduct Target Ther. 2020 Oct 19;5(1):157
pubmed: 32814760
Osong Public Health Res Perspect. 2020 Jun;11(3):101-111
pubmed: 32528815
Signal Transduct Target Ther. 2022 Apr 5;7(1):114
pubmed: 35383141
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Vaccine. 2012 Dec 17;31(1):58-83
pubmed: 23142589
Biochim Biophys Acta Gen Subj. 2021 Jun;1865(6):129893
pubmed: 33731300
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Lancet Respir Med. 2022 Feb;10(2):167-179
pubmed: 34800364
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
J Clin Invest. 2021 Jul 1;131(13):
pubmed: 34003804
Front Immunol. 2022 Mar 16;13:845887
pubmed: 35371043
Nat Med. 2020 Sep;26(9):1422-1427
pubmed: 32651581
Hum Vaccin Immunother. 2021 Aug 3;17(8):2356-2366
pubmed: 33847226
Virus Res. 2020 Oct 15;288:198114
pubmed: 32800805
Viruses. 2020 Sep 10;12(9):
pubmed: 32927639
Science. 2021 Jul 23;373(6553):397-399
pubmed: 34437109
Front Immunol. 2020 Aug 19;11:1880
pubmed: 32973779
Emerg Microbes Infect. 2022 Dec;11(1):1058-1071
pubmed: 35311493
Front Cell Infect Microbiol. 2021 Sep 10;11:690621
pubmed: 34568087
PLoS One. 2013;8(2):e55438
pubmed: 23437055
Expert Rev Vaccines. 2011 Apr;10(4):437-46
pubmed: 21506642
Cell Rep Med. 2021 Jul 20;2(7):100355
pubmed: 34230917
Vaccine. 2008 Aug 26;26(36):4664-8
pubmed: 18639601
Immunity. 2021 Dec 14;54(12):2908-2921.e6
pubmed: 34788600
Brain. 2021 Dec 31;144(12):3576-3588
pubmed: 34398188
Expert Rev Vaccines. 2008 Oct;7(8):1141-50
pubmed: 18844588
Immunohorizons. 2018 Jul 2;2(6):185-197
pubmed: 31022686
EBioMedicine. 2021 Dec;74:103699
pubmed: 34801965
Small Methods. 2021 Sep 15;5(9):2100402
pubmed: 34514087
Nature. 2021 Jun;594(7862):253-258
pubmed: 33873199
NPJ Vaccines. 2020 May 18;5(1):41
pubmed: 32435515
Vaccine. 2017 Mar 7;35(10):1448-1454
pubmed: 28190741
Sci Immunol. 2021 Jul 15;6(61):
pubmed: 34266981
J Allergy Clin Immunol. 2020 Sep;146(3):479-491.e5
pubmed: 32896308
Antimicrob Agents Chemother. 2000 May;44(5):1163-7
pubmed: 10770746
Vaccine. 2009 Jul 16;27(33):4381-7
pubmed: 19450630
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992388
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):14857-14863
pubmed: 32527856
Expert Rev Vaccines. 2013 Jul;12(7):779-91
pubmed: 23885823
PLoS Pathog. 2021 Sep 3;17(9):e1009885
pubmed: 34478455
Rev Med Virol. 2022 Jul;32(4):e2313
pubmed: 34755408
PLoS Pathog. 2010 Jul 22;6(7):e1001005
pubmed: 20661479
EBioMedicine. 2022 Sep;83:104217
pubmed: 35970020
Immunity. 2021 Mar 9;54(3):542-556.e9
pubmed: 33631118
EMBO Mol Med. 2021 Dec 7;13(12):e14544
pubmed: 34672091
Int J Pharm. 2021 May 15;601:120586
pubmed: 33839230
Nature. 2021 Jun;594(7864):553-559
pubmed: 33971664
Vaccine. 2020 Dec 14;38(52):8264-8272
pubmed: 33229108
Commun Biol. 2021 Nov 22;4(1):1317
pubmed: 34811480
Infection. 2022 Feb;50(1):11-25
pubmed: 34324165
Nat Commun. 2021 Feb 24;12(1):1260
pubmed: 33627662
Clin Immunol. 2017 Oct;183:99-108
pubmed: 28780375
Front Immunol. 2022 Apr 05;13:857440
pubmed: 35479095
Cell Mol Immunol. 2020 Jun;17(6):613-620
pubmed: 32203189
Science. 2021 Oct 22;374(6566):472-478
pubmed: 34554826
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Nat Commun. 2022 Aug 24;13(1):4958
pubmed: 36002453
PLoS One. 2011;6(7):e22273
pubmed: 21799810
Cell. 2022 Jul 7;185(14):2434-2451.e17
pubmed: 35764089
Appl Microbiol Biotechnol. 2021 May;105(10):4153-4165
pubmed: 33959781
J Prev Med Hyg. 2010 Mar;51(1):1-6
pubmed: 20853669
J Clin Med. 2020 Apr 24;9(4):
pubmed: 32344679
Vaccine. 2022 May 3;40(20):2841-2847
pubmed: 35397946
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Euro Surveill. 2020 Apr;25(13):
pubmed: 32265007
Expert Opin Biol Ther. 2008 Aug;8(8):1177-85
pubmed: 18613769
J Med Virol. 2020 Oct;92(10):2096-2104
pubmed: 32383254
PLoS Biol. 2018 Aug 13;16(8):e3000003
pubmed: 30102691
Vaccine. 2010 Aug 2;28(34):5543-50
pubmed: 20600502
Cell. 2020 Sep 3;182(5):1284-1294.e9
pubmed: 32730807
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Front Immunol. 2021 Jun 04;12:691715
pubmed: 34149735
J Clin Invest. 1992 Dec;90(6):2491-5
pubmed: 1334977
Sci Rep. 2022 Mar 10;12(1):3884
pubmed: 35273217
Int J Biol Macromol. 2021 Jul 1;182:648-658
pubmed: 33862071
Infect Dis Poverty. 2020 Apr 28;9(1):45
pubmed: 32345362
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
Clin Microbiol Infect. 2022 Feb;28(2):202-221
pubmed: 34715347
Vaccines (Basel). 2021 Sep 06;9(9):
pubmed: 34579229
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Front Med (Lausanne). 2022 Feb 22;9:815389
pubmed: 35273977
J Clin Invest. 2011 May;121(5):1782-96
pubmed: 21540549
ACS Nano. 2021 Nov 23;15(11):16982-17015
pubmed: 34181394
NPJ Vaccines. 2021 Oct 28;6(1):128
pubmed: 34711846
Virus Res. 2004 Jul;103(1-2):139-45
pubmed: 15163502
Cell. 2019 May 16;177(5):1153-1171.e28
pubmed: 31080066
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Vaccine. 2011 Jul 26;29(33):5434-42
pubmed: 21641953
Front Mol Biosci. 2021 Apr 22;8:671633
pubmed: 33968996
N Engl J Med. 2022 Jun 9;386(23):2201-2212
pubmed: 35613036
Proteins. 2021 May;89(5):569-576
pubmed: 33423311
Nature. 2020 May;581(7807):215-220
pubmed: 32225176